208 related articles for article (PubMed ID: 29950327)
21. Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis.
Nagafuchi H; Atsumi T; Hatta K; Muso E; Takeno M; Yamada H; Ozaki S
Mod Rheumatol; 2015 Jul; 25(4):603-8. PubMed ID: 25496405
[TBL] [Abstract][Full Text] [Related]
22. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Pepper RJ; Draibe JB; Caplin B; Fervenza FC; Hoffman GS; Kallenberg CG; Langford CA; Monach PA; Seo P; Spiera R; William St Clair E; Tchao NK; Stone JH; Specks U; Merkel PA; Salama AD;
Arthritis Rheumatol; 2017 Jan; 69(1):185-193. PubMed ID: 27428710
[TBL] [Abstract][Full Text] [Related]
23. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
[TBL] [Abstract][Full Text] [Related]
24. Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.
Fussner LA; Hummel AM; Schroeder DR; Silva F; Cartin-Ceba R; Snyder MR; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; William St Clair E; Tchao NK; Stone JH; Specks U;
Arthritis Rheumatol; 2016 Jul; 68(7):1700-10. PubMed ID: 26882078
[TBL] [Abstract][Full Text] [Related]
25. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.
Pepper RJ; McAdoo SP; Moran SM; Kelly D; Scott J; Hamour S; Burns A; Griffith M; Galliford J; Levy JB; Cairns TD; Gopaluni S; Jones RB; Jayne D; Little MA; Pusey CD; Salama AD
Rheumatology (Oxford); 2019 Feb; 58(2):260-268. PubMed ID: 30239910
[TBL] [Abstract][Full Text] [Related]
26. [Recommendations on the use of rituximab for ANCA-associated vasculitis].
Gause AM; Rubbert-Roth A;
Z Rheumatol; 2014 Apr; 73(3):287-9. PubMed ID: 27039911
[TBL] [Abstract][Full Text] [Related]
27. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.
McGregor JG; Hogan SL; Kotzen ES; Poulton CJ; Hu Y; Negrete-Lopez R; Kidd JM; Katsanos SL; Bunch DO; Nachman PH; Falk RJ
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1(Suppl 1):i123-31. PubMed ID: 25805743
[TBL] [Abstract][Full Text] [Related]
28. Severe infections in patients with ANCA-associated vasculitis treated with rituximab.
Segelmark L; Flores-Suárez L; Mohammad A
Rheumatology (Oxford); 2021 Dec; 61(1):205-212. PubMed ID: 33757116
[TBL] [Abstract][Full Text] [Related]
29. Effect of Continuous B Cell Depletion With Rituximab on Pathogenic Autoantibodies and Total IgG Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Cortazar FB; Pendergraft WF; Wenger J; Owens CT; Laliberte K; Niles JL
Arthritis Rheumatol; 2017 May; 69(5):1045-1053. PubMed ID: 28029751
[TBL] [Abstract][Full Text] [Related]
30. Response to: 'Prevention of infections in patients with antineutrophil cytoplasm antibody-associated vasculitis: potential role of hydroxychloroquine' by Novikov
Kronbichler A; Jayne D
Ann Rheum Dis; 2020 Feb; 79(2):e20. PubMed ID: 30700426
[No Abstract] [Full Text] [Related]
31. Severe Infection in Antineutrophil Cytoplasmic Antibody-associated Vasculitis.
Mohammad AJ; Segelmark M; Smith R; Englund M; Nilsson JÅ; Westman K; Merkel PA; Jayne DRW
J Rheumatol; 2017 Oct; 44(10):1468-1475. PubMed ID: 28765251
[TBL] [Abstract][Full Text] [Related]
32. Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study.
Yang L; Xie H; Liu Z; Chen Y; Wang J; Zhang H; Ge Y; Hu W
BMC Nephrol; 2018 Jun; 19(1):138. PubMed ID: 29902982
[TBL] [Abstract][Full Text] [Related]
33. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
34. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis.
Kronbichler A; Jayne DR; Mayer G
Eur J Clin Invest; 2015 Mar; 45(3):346-68. PubMed ID: 25627555
[TBL] [Abstract][Full Text] [Related]
35. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.
Jones RB
Nephron Clin Pract; 2014; 128(3-4):243-9. PubMed ID: 25401382
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of rituximab versus azathioprine for maintenance treatment in antineutrophil cytoplasmic antibody-associated vasculitis.
Montante A; Le Bras A; Pagnoux C; Perrodeau E; Ravaud P; Terrier B; Guillevin L; Durand-Zaleski I;
Clin Exp Rheumatol; 2019; 37 Suppl 117(2):137-143. PubMed ID: 31162031
[TBL] [Abstract][Full Text] [Related]
38. Characteristics and Visual Outcome of Refractory Retinal Vasculitis Associated With Antineutrophil Cytoplasm Antibody-Associated Vasculitides.
Lin M; Anesi SD; Ma L; Ahmed A; Small K; Foster CS
Am J Ophthalmol; 2018 Mar; 187():21-33. PubMed ID: 29258731
[TBL] [Abstract][Full Text] [Related]
39. Protective effect of different doses of trimethoprim-sulfamethoxazole prophylaxis for early severe infections among patients with antineutrophil cytoplasmic autoantibody-associated vasculitis.
Waki D; Nishimura K; Yoshida T; Tanaka N; Mizukawa K; Fukushima M; Iri O; Anegawa M; Murabe H; Yokota T
Clin Exp Rheumatol; 2021; 39 Suppl 129(2):142-148. PubMed ID: 33734974
[TBL] [Abstract][Full Text] [Related]
40. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
Shah S; Hruskova Z; Segelmark M; Morgan MD; Hogan J; Lee SK; Dale J; Harper L; Tesar V; Jayne DR; Geetha D
Am J Nephrol; 2015; 41(4-5):296-301. PubMed ID: 26044574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
